- Home
- POAI vs NCNA Comparison
POAI vs NCNA Comparison
Compare POAI & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | POAI | NCNA |
|---|---|---|
| Founded | 2002 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 7.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | POAI | NCNA |
|---|---|---|
| Price | $5.58 | $3.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.7K | ★ 65.1K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,664,407.00 | N/A |
| Revenue This Year | $486.27 | N/A |
| Revenue Next Year | $65.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 320.71 | N/A |
| 52 Week Low | $3.88 | $2.78 |
| 52 Week High | $45.90 | $330.00 |
Technical Indicators
Market Signals| Indicator | POAI | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 43.81 |
| Support Level | $3.88 | $4.10 |
| Resistance Level | $6.25 | $4.55 |
| Average True Range (ATR) | 0.76 | 0.28 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 79.01 | 1.29 |
Price Performance
Historical ComparisonAbout POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.